Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFerrexpo Regulatory News (FXPO)

  • This share is currently suspended. It was suspended at a price of 28.58

Share Price Information for Ferrexpo (FXPO)

Share Price is delayed by 15 minutes
Get Live Data
28.58    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: £168.16m
FXPO Live PriceLast checked at - London Stock Exchange

Intraday Ferrexpo Share Chart

New Credit Facility

2 Sep 2011 07:00

RNS Number : 5118N
Ferrexpo PLC
02 September 2011
 



2 September 2011

Ferrexpo plc

("Ferrexpo", the "Group" or the "Company")

 

New Credit Facility

 

Ferrexpo is pleased to announce that it has secured a new credit facility of US$420 million ("the credit facility"). The credit facility can be drawn at any time during the loan term which has a maturity of 5 years including amortization over 2 years.

 

The new credit facility carries a cost of 225bps above LIBOR on drawn amounts, and will initially remain undrawn.

 

ING Bank N.V., UniCredit Bank AG, and Société Générale Corporate and Investment Banking acted as Co-ordinating Mandated Lead Arrangers alongside 7 other prominent financial institutions:

 

·; UniCredit Bank Austria AG

·; West LB AG

·; ICBC London plc

·; ABN Amro Bank N.V.

·; Credit Suisse AG

·; J.P. Morgan Limited

·; Citibank N.A.

 

The Co-ordinating Mandated Lead Arrangers together with West LB and ICBC acted as book runners. UniCredit Bank AG acted as Documentation Co-ordinator, ING the Facility Agent, and ICBC as Credit Support Account Agent.

 

Chris Mawe, Chief Financial Officer of Ferrexpo said:

 

"This new credit facility is testimony to the strength of Ferrexpo's balance sheet and the quality of the business. The size and tenor of the facility complements the Group's recent US$500 million Eurobond issue and provides the necessary financial flexibility to continue to develop the Group's significant project pipeline."

 

For further information, please contact:

 

Ferrexpo:

Ingrid McMahon

+44 207 389 8304

Pelham Bell Pottinger

Charles Vivian

+44 207 861 3126

James Macfarlane

+44 207 861 3864

 

Notes to Editors:

 

Ferrexpo is a Swiss headquartered iron ore company with assets in Ukraine. It is principally involved in the production and export of high quality iron ore pellets, which are used in the manufacture of steel. Ferrexpo's resource base is one of the largest iron ore deposits in the world. Its current producing asset, FPM, produced approximately 10 million tonnes of iron ore pellets in 2010 making it the largest exporter of pellets in the CIS. The Company has a diversified customer base supplying steel mills in Austria, Serbia, Slovakia, Czech Republic, Germany and other European states, as well as in China, India, Japan, and other Asian countries. Ferrexpo is listed on the main market of the London Stock Exchange under the ticker FXPO. For further information, please visit www.ferrexpo.com 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUUSVRAAAKRRR
Date   Source Headline
15th Mar 20237:00 amRNSFull Year Financial Results for 2022
10th Mar 20237:00 amRNSTransfer of Treasury Shares & Total Voting Rights
7th Mar 20234:17 pmRNSResponse to Media Report
2nd Mar 20234:53 pmRNSTR-1: Notification of major holdings
1st Mar 20237:00 amRNSNotice of Full Year Results
7th Feb 20237:00 amRNSUpdate Regarding Subsidiary’s Accounts in Ukraine
11th Jan 20237:00 amRNSProduction Report and Trading Update for 4Q 2022
3rd Jan 20237:00 amRNSResignation of Non-executive Director
29th Dec 20224:54 pmRNSUpdate Regarding Non-executive Director
29th Dec 20227:00 amRNSUpdate Regarding Non-executive Director
23rd Dec 20229:34 amRNSDirector/PDMR Shareholding
21st Dec 20227:00 amRNSOperations Update
8th Dec 20227:00 amRNSPublication of Climate Change Report
17th Nov 20223:07 pmRNSHolding(s) in Company
11th Nov 20229:00 amRNSHolding(s) in Company
1st Nov 20227:00 amRNSOperations Update
11th Oct 20227:00 amRNSOperations Update
6th Oct 20227:00 amRNSProduction Report for 3Q 2022
22nd Sep 20222:51 pmRNSTR-1: Notification of major holdings
20th Sep 20227:00 amRNSAppeal Court Ruling in Ukraine
19th Sep 20222:19 pmRNSHolding(s) in Company
5th Aug 20221:06 pmRNSDirector/PDMR Shareholding
3rd Aug 20227:01 amRNSPublication of Responsible Business Report
3rd Aug 20227:00 amRNSInterim Results for six months ended 30 June 2022
25th Jul 20227:00 amRNSCompletion of External Assurance Process
19th Jul 20227:00 amRNSNotice of Interim Results
18th Jul 20225:06 pmRNSTR-1: Notification of major holdings
7th Jul 20227:00 amRNSProduction Report for 2Q 2022
5th Jul 20225:25 pmRNSDirector/PDMR Shareholding
29th Jun 20222:07 pmRNSReport on Payments to Governments for 2021
29th Jun 202211:05 amRNSDirector/PDMR Shareholding
23rd Jun 202212:59 pmRNSTR-1: Notification of major holdings
21st Jun 20224:13 pmRNSTR-1: Notification of major holdings
15th Jun 202212:50 pmRNSResults of AGM and General Meeting
15th Jun 20227:00 amRNSAGM Presentation & Chair Address
13th Jun 20227:00 amRNSLogistics and Operations Update
7th Jun 20222:01 pmRNSDirector/PDMR Shareholding
31st May 20227:00 amRNSAnnouncement of Interim Dividend
10th May 202212:08 pmRNSCircular and Notice of General Meeting
10th May 20227:00 amRNSNotice of AGM, 2021 ARA and Proposed 2021 Dividend
22nd Apr 20227:20 amRNS2021 Full Year Financial Results
21st Apr 20227:00 amRNSIncrease in Humanitarian Fund to US$12.5 Million
20th Apr 20223:30 pmRNSHolding(s) in Company
8th Apr 20227:00 amRNSProduction Report and Trading Update for 1Q 2022
29th Mar 20227:00 amRNSHumanitarian Fund Update and Partner Support
28th Mar 20224:00 pmRNSDirector Declaration
18th Mar 20227:00 amRNSExtension of Financial Accounts Deadline
14th Mar 20227:00 amRNSHumanitarian Fund Expanded to US$7.5 Million
7th Mar 20227:00 amRNSHumanitarian Fund to Support Ukraine
28th Feb 20227:00 amRNSCorporate and Logistics Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.